Chronic News and Research

RSS

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA).

23 Feb 2013

Physicians afraid to give thrombolytic drugs to pulmonary embolism patients for good reason

When doctors encounter a patient with a massive pulmonary embolism, they face a difficult choice: Is it wise to administer a drug that could save the patient's life, even though many people suffer life-threatening bleeding as a result? Based on new findings published in the American Journal of Medicine, Michigan State University researchers are answering that question in no uncertain terms.

22 Feb 2013

Florida Hospital Pepin Heart Institute, USF partner for novel gene therapy trial

Cardiovascular disease specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute affiliated with the University of South Florida announced they have enrolled their first patients into a clinical trial testing a novel gene therapy for the treatment of heart failure after ischemic injury. The therapy may promote the regeneration of heart tissue by encouraging the body to deploy more stem cells to the injury site.

22 Feb 2013

Study finds bariatric surgery does not reduce long-term medical costs

Research disputes widely-held beliefs that the weight-loss operations cut the need for treatments and medicine after patients shed pounds.

22 Feb 2013

Study shows how hyperparathyroidism affects people of different racial backgrounds

Unusually high calcium levels in the blood can almost always be traced to primary hyperparathyroidism, an undertreated, underreported condition that affects mainly women and the elderly, according to a new study by UCLA researchers.

22 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

Targeting CSF1R with selective inhibitors could help Alzheimer's

Scientists from the University of Southampton have identified the molecular system that contributes to the harmful inflammatory reaction in the brain during neurodegenerative diseases.

22 Feb 2013

Brain cooling after severe head injury may prevent epileptic seizures

In the weeks, months and years after a severe head injury, patients often experience epileptic seizures that are difficult to control. A new study in rats suggests that gently cooling the brain after injury may prevent these seizures.

22 Feb 2013

EASL unveils new publication - The burden of liver disease in Europe

Major progress has been made in the past 30 years in the knowledge and management of liver disease, yet approximately 29 million Europeans still suffer from a chronic liver condition. The European Association for the Study of the Liver (EASL) today unveiled its new publication The burden of liver disease in Europe: a review of available epidemiological data.

22 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Charles L. Sawyers, Chair of Memorial Sloan-Kettering's Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today. The award - established by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner - recognizes "excellence in research aimed at curing intractable diseases and extending human life."

21 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Eliminating insurance co-payments can improve medication adherence and management of diabetes

Reducing financial barriers to medication access—a strategy known as value-based insurance design (VBID)—can improve medication adherence and management of chronic diseases such as diabetes.

21 Feb 2013

Patients with Barrett's esophagus benefit from endoscope-based therapies

According to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania, patients with Barrett's esophagus and early or pre-cancerous cells have been shown to significantly benefit from minimally invasive therapy delivered through an endoscope - a medical instrument used to look inside an organ or cavity in the body.

21 Feb 2013

Sixth death from novel coronavirus recorded in Britain

"A British man infected with a new virus from the same family as SARS has died, health officials said on Tuesday, bringing the worldwide death toll from the previously unknown disease to six," Reuters reports.

21 Feb 2013

Tips to help reduce dry eyes

Some of the last days of winter can be among the worst for your eyes. Winter may be slowly giving way to spring, but the remaining cold days of the season can cause plenty of trouble for the eyes—trouble that is largely avoidable, says a Vanderbilt Eye Institute ophthalmologist.

21 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

Bracelet-like device with magnetic beads can control gastroesophageal reflux disease

A bracelet-like device with magnetic beads can control the chronic digestive disorder gastroesophageal reflux disease, according to a study published online today in the New England Journal of Medicine.

21 Feb 2013

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

Selenium is a micronutrient which has antioxidant properties by means of selenoproteins which play many important functions in the body. They actually are contained in many different foods. The amount of selenium we get from diet is closely linked to the amount of selenium in the soil.

21 Feb 2013

Ultrathin nanowire-based electrode helps capture signals from brain nerve cells

Electrodes operated into the brain are today used in research and to treat diseases such as Parkinson's. However, their use has been limited by their size. At Lund University in Sweden, researchers have, for the first time, succeeded in implanting an ultrathin nanowire-based electrode and capturing signals from the nerve cells in the brain of a laboratory animal.

21 Feb 2013

Chronic News and Research

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Physicians afraid to give thrombolytic drugs to pulmonary embolism patients for good reason

Florida Hospital Pepin Heart Institute, USF partner for novel gene therapy trial

Study finds bariatric surgery does not reduce long-term medical costs

Study shows how hyperparathyroidism affects people of different racial backgrounds

Janssen submits simeprevir regulatory application in Japan to treat HCV

Targeting CSF1R with selective inhibitors could help Alzheimer's

Brain cooling after severe head injury may prevent epileptic seizures

EASL unveils new publication - The burden of liver disease in Europe

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

Eliminating insurance co-payments can improve medication adherence and management of diabetes

Patients with Barrett's esophagus benefit from endoscope-based therapies

Sixth death from novel coronavirus recorded in Britain

Tips to help reduce dry eyes

Daclatasvir has two primary modes of action against HCV

Bracelet-like device with magnetic beads can control gastroesophageal reflux disease

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

Ultrathin nanowire-based electrode helps capture signals from brain nerve cells

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News